The trajectory of companies tied to the drug's legacy presents a complex investment landscape. While the initial success generated substantial gains, generic alternatives have significantly diminished sales . Investing in connected pharmaceutical firms now requires a careful assessment of patent safeguards, evolving healthcare shifts , and the pros